Combining desloratadine and pseudoephedrine in the treatment of seasonal allergic rhinitis

References

• Bachert C, Van Cauwenberge P, Khaltaev N. Allergic Rhinitis and its Impact on Asthma (ARIA) in collaboration with the World Health Organization. Executive Summary of the Workshop Report, 7–10 December 1999, Geneva, Switzerland. Allergy57(9), 841–855 (2002). Erratum in: Allergy57(12), 1208. Bousquet J [corrected to Bachert C] (2002).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bullinger M, Fayol C et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J. Allergy Clin. Immunol.94(2 Pt 1), 182–188 (1994).
   PubMed Web of Science ®Google Scholar
• Meltzer EO. The prevalence and medical and economic impact of allergic rhinitis in the United States. J. Allergy Clin. Immunol.99, S805–S828 (1997).
   PubMed Web of Science ®Google Scholar
• Malone DC, Lawson KA, Smith DH, Arrighi HM, Battista C. A cost of illness study of allergic rhinitis in the United States. J. Allergy Clin. Immunol.99(1 Pt 1), 22–27 (1997).
   PubMed Web of Science ®Google Scholar
• Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J. Allergy Clin. Immunol.108, S2–S8 (2001).
   PubMed Web of Science ®Google Scholar
• Skoner D, Doyle W, Boehm S, Fireman P. Late phase eustachian tube and nasal allergic responses associated with inflammatory mediator elaboration. Am. J. Rhinol.2, 155–161 (1988).
   Google Scholar
• Roper Public Affairs Group of NOP World. Impact of nasal congestion among allergic rhinitis sufferers. An internet survey of 2002 people. May–June (2004).
   Google Scholar
• Corey JP, Houser SM, Ng BA. Nasal congestion: a review of its etiology, evaluation, and treatment. Ear Nose Throat J.79(9), 690–693, 696, 698 passim (2000).
   PubMedGoogle Scholar
• Skoner DP. Complications of allergic rhinitis. J. Allergy Clin. Immunol.105(6 Pt 2), S605–S609 (2000).
   PubMed Web of Science ®Google Scholar
• Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J. Allergy Clin. Immunol.99(2), S757–S762 (1997).
   Google Scholar
• Binder E, Holopainen E, Malmberg H, Salo O. Anamnestic data in allergic rhinitis. Allergy37(6), 389–396 (1982).
   PubMed Web of Science ®Google Scholar
• Reinberg A, Gervais P, Levi F et al. Circadian and circannual rhythms of allergic rhinitis: an epidemiologic study involving chronobiologic methods. J. Allergy Clin. Immunol.81(1), 51–62 (1988).
   PubMed Web of Science ®Google Scholar
• Simons FE. Advances in H1-antihistamines. N. Engl. J. Med.351(21), 2203–2217 (2004).
   PubMed Web of Science ®Google Scholar
• Dykewicz MS, Fineman S, Skoner DP et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann. Allergy Asthma Immunol.81(5 Pt 2), 478–518 (1998).
   PubMed Web of Science ®Google Scholar
• Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy56(Suppl. 65), 14–20 (2001).
   PubMed Web of Science ®Google Scholar
• Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy56(11), 1077–1080 (2001).
   PubMed Web of Science ®Google Scholar
• Holmberg K, Tonnel AB, Dreyfus I et al. Desloratadine reduces nasal congestion in persistent (perennial) allergic rhinitis. Proceedings of the XXIII EAACI Congress. Amsterdam, The Netherlands, 84. Abstract 261 and poster (2004).
   Google Scholar
• Wilson AM, Haggart K, Sims EJ et al. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin. Exp. Allergy32(10), 1504–1509 (2002).
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cirillo I, Vizzaccaro A et al. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin. Exp. Allergy34(6), 958–964 (2004).
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy56(11), 1068–1070 (2001).
   PubMed Web of Science ®Google Scholar
• Horak F, Stübner P, Zieglmayer R et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int. Arch. Allergy Immunol.125(1), 73–79 (2001).
   PubMed Web of Science ®Google Scholar
• Corren J, Harris AG, Aaronson D et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J. Allergy Clin. Immunol.100(6 Pt 1), 781–788 (1997).
   PubMed Web of Science ®Google Scholar
• Georgitis JW, Meltzer EO, Kaliner M, Weiler J, Berkowitz R. Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge. Ann. Allergy Asthma Immunol.84(4), 451–459 (2000).
   PubMed Web of Science ®Google Scholar
• Berkowitz RB, McCafferty F, Lutz C et al. Fexofenadine HCl 60 mg/pseudoephedrine HCl 120 has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit. Allergy Asthma Proc.25(5), 335–343 (2004).
   PubMed Web of Science ®Google Scholar
• Wellington K, Jarvis B. Cetirizine/pseudoephedrine. Drugs61(15), 2231–2240 (2001).
   PubMed Web of Science ®Google Scholar
• Simola M, Boss I, Holopainen E et al. Astemizole in combination with pseudoephedrine in the treatment of seasonal allergic rhinitis. Rhinology34(1), 21–23 (1996).
   PubMedGoogle Scholar
• Schenkel E, Corren J, Murray JJ. Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc.23(5), 325–330 (2002).
   PubMed Web of Science ®Google Scholar
• Pleskow W, Grubbe R, Weiss S, Lutsky B. Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol.94(3), 348–354 (2005).
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Casale TB, Gold MS et al. Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study. Ann. Allergy Asthma Immunol.90(1), 79–86 (2003).
   PubMed Web of Science ®Google Scholar
• Clarinex® (desloratadine) tablets, syrup, Reditabs tablets [package insert]. Schering Corporation, Kenilworth, NJ 07033 USA. (2004).
   Google Scholar
• Clarinex-D® 24 Hour (desloratadine 5 mg and pseudoephedrine sulfate, USP 240 mg) extended release tablets [product information]. Schering Corporation, Kenilworth, NJ 07033 USA. (2005).
   Google Scholar
• Agrawal DK. Anti-inflammatory properties of desloratadine. Clin. Exp. Allergy34(9), 1342–1348 (2004).
   PubMed Web of Science ®Google Scholar
• Bachert C. Therapeutic points of intervention and clinical implications: role of desloratadine. Allergy57(Suppl. 75), 13–18 (2002).
   PubMedGoogle Scholar
• Wilken JA, Daly AF, Sullivan CL, Kim H. Desloratadine for allergic rhinitis. Exp. Rev. Clin. Immunol.2(2), 209–224 (2006).
   PubMedGoogle Scholar
• Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat. Respir. Med.4(1), 21–29 (2005).
   PubMedGoogle Scholar
• Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam. Pract.3(1), 14 (2002).
   PubMedGoogle Scholar
• Clarinex-D® 12 Hour (desloratadine 2.5 mg and pseudoephedrine sulfate, USP 120 mg) extended release tablets [product information]. Schering Corporation, Kenilworth, NJ 07033 USA (2006).
   Google Scholar
• Anthes JC, Gilchrest H, Richard C et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur. J. Pharmacol.449(3), 229–237 (2002).
   PubMed Web of Science ®Google Scholar
• Kreutner W, Hey JA, Anthes J et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung50(4), 345–352 (2000).
   PubMed Web of Science ®Google Scholar
• Kreutner W, Hey JA, Chiu P, Barnett A. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects. Arzneimittelforschung50(5), 441–448 (2000).
   PubMed Web of Science ®Google Scholar
• Wilken JA, Kane RL, Ellis AK et al. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. Ann. Allergy Asthma Immunol.91(4), 375–385 (2003).
   PubMed Web of Science ®Google Scholar
• Marino M, Glue P, Herron JM. Lack of electrocardiographic effects of multiple high doses of desloratadine. Allergy55(Suppl. 63), 279 (2000).
   Google Scholar
• Affrime M, Gupta S, Banfield C, Cohen A. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin. Pharmacokinet.41(Suppl. 1), 13–19 (2002).
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Prenner BM, Nayak A, the Desloratadine Study Group. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis assessment during the spring and fall allergy seasons. Clin. Drug Invest.21(1), 25–32 (2001).
   Web of Science ®Google Scholar
• Berger WE, Schenkel EJ, Mansfield LE, the Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann. Allergy Asthma Immunol.89(5), 485–491 (2002).
   PubMed Web of Science ®Google Scholar
• Simons FE, Prenner BM, Finn A Jr, the Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J. Allergy Clin. Immunol.111(3), 617–622 (2003).
   PubMed Web of Science ®Google Scholar
• Gupta S, Banfield C, Affrime M et al. Desloratadine demonstrates dose proportionality in healthy adults after single doses. Clin. Pharmacokinet.41(Suppl. 1), 1–6 (2002).
   PubMed Web of Science ®Google Scholar
• DuBuske LM. Pharmacology of desloratadine: special characteristics. Clin. Drug Invest.22(S2), 1–11 (2002).
   PubMedGoogle Scholar
• Ghosal A, Yuan Y, Hapangama N et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Biopharm. Drug Dispos.25(6), 243–252 (2004).
   PubMed Web of Science ®Google Scholar
• Khalilieh S, Lutsky B, Lorber R. Safety of desloratadine in poor metabolizers. Annual Meeting of the American College of Allergy, Asthma and Immunology. Boston, MA, USA, November 12–17 (2004).
   Google Scholar
• Gupta S, Kantesaria B, Wang Z, Khalilieh S. Pharmacokinetics of desloratadine in poor metabolizers. Annual Meeting of American College of Allergy, Asthma and Immunology. Boston, MA, USA, November 12–17 (2004).
   Google Scholar
• Affrime M, Banfield C, Gupta S et al. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clin. Pharmacokinet.41(Suppl. 1), 21–28 (2002).
   PubMed Web of Science ®Google Scholar
• Benezra SA, McRae JW. Pseudoephedrine hydrochloride. In: Analytical Profiles of Drug Substances. Florey K (Ed.). Academic Press, NY, USA, 489–507 (1979).
   Google Scholar
• Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy13(6 Pt 2), S116–S128 (1993).
   PubMed Web of Science ®Google Scholar
• Gupta S, Banfield C, Affrime M et al. Oral bioavailability of desloratadine is unaffected by food. Clin. Pharmacokinet.41(Suppl. 1), 7–12 (2002).
   PubMed Web of Science ®Google Scholar
• Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin. Pharmacokinet.41(4), 311–318 (2002).
   PubMed Web of Science ®Google Scholar
• Bailey DG. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol.46(2), 101–110 (1998).
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG, Leake BF et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther.71(1), 11–20 (2002).
   PubMed Web of Science ®Google Scholar
• Barecki ME, Casciano CN, Johnson WW, Clement RP. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab. Dispos.29(9), 1173–1175 (2001).
   PubMed Web of Science ®Google Scholar
• Wang EJ, Casciano CN, Clement RP, Johnson WW. Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab. Dispos.29(8), 1080–1083 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta S, Banfield C, Kantesaria B, Flannery B, Herron J. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J. Clin. Pharmacol.44(11), 1252–1259 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta S, Banfield C, Kantesaria B et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin. Ther.23(3), 451–466 (2001).
   PubMed Web of Science ®Google Scholar
• Banfield C, Herron J, Keung A, Padhi D, Affrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin. Pharmacokinet.41(Suppl. 1), 37–44 (2002).
   PubMed Web of Science ®Google Scholar
• Banfield C, Hunt T, Reyderman L et al. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin. Pharmacokinet.41(Suppl. 1), 29–35 (2002).
   PubMed Web of Science ®Google Scholar
• Khalilieh S, Krishna G, Marino M et al. Lack of interaction with coadministration of desloratadine and cimetidine. Ann. Allergy Asthma Immunol.88, 110 (2002).
   Google Scholar
• Haye R, Høye K, Berg O et al. Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomized controlled study [ISRCTN23032971]. Clin. Mol. Allergy3(3) (2005).
   Google Scholar
• Kim KT, Sussman GL, Herbert J et al. Effect of once-daily desloratadine in patients with perennial allergic rhinitis (PAR): a double-blind, placebo-controlled study. J. Allergy Clin. Immunol.111, S76–S77 Abstract 25 (2003).
   Google Scholar
• Horak F, Stübner UP, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J. Allergy Clin. Immunol.109(6), 956–961 (2002).
   PubMed Web of Science ®Google Scholar
• Horak F, Stübner P, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy58(6), 481–485 (2003).
   PubMed Web of Science ®Google Scholar
• Bhatia S, Baroody FM, deTineo M, Naclerio RM. Increased nasal airflow with budesonide compared with desloratadine during the allergy season. Arch. Otolaryngol. Head Neck Surg.131(3), 223–228 (2005).
   PubMedGoogle Scholar
• Hamilton LH, Chobanian SL, Cato A, Perkins JG. A study of sustained action pseudoephedrine in allergic rhinitis. Ann. Allergy48(2), 87–92 (1982).
   PubMedGoogle Scholar
• Roth RP, Cantekin EI, Bluestone CD, Welch RM, Cho YW. Nasal decongestant activity of pseudoephedrine. Ann. Otol. Rhinol. Laryngol.86(2 Pt 1), 235–242 (1977).
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Nayak A, Rooklin A, Danzig M. Efficacy and safety of desloratadine/pseudoephedrine tablet, 2.5/120 two times a day, versus individual components in the treatment of patients with seasonal allergic rhinitis. Allergy Asthma Proc.26, 391–396 (2005).
   PubMed Web of Science ®Google Scholar
• Kerney D. Real world treatment with desloratadine in seasonal allergic rhinitis (SAR) patients. Ann. Allergy Asthma Immunol.90, 123 (2003).
   Google Scholar
• Bachert C, Virchow JC, Plenker A. Desloratadine in the treatment of seasonal allergic rhinitis: results of a large observational study. Clin. Drug Invest.22(Suppl. 2), 43–52 (2002).
   Web of Science ®Google Scholar
• Vuurman EF, Rikken G, Muntjewerff ND, de Halleux F, Ramaekers JG. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur. J. Clin. Pharmacol.60(5), 307–313 (2004).
   PubMed Web of Science ®Google Scholar
• Valk PJ, Van Roon DB, Simons RM, Rikken G. Desloratadine shows no effect on performance during 6 h at 8,000 ft simulated cabin altitude. Aviat. Space Environ. Med.75(5), 433–438 (2004).
   PubMed Web of Science ®Google Scholar
• Nicholson AN, Handford ADF, Turner C, Stone BM. Studies on performance and sleepiness with the H-1-antihistamine, desloratadine. Aviat. Space Environ. Med.74(8), 809–815 (2003).
   PubMed Web of Science ®Google Scholar
• Satish U, Streufert S, Dewan M, Voort SV. Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine. Allergy59(4), 415–420 (2004).
   PubMed Web of Science ®Google Scholar
• Neoclarityn® (desloratadine) 0.5 mg/ml syrup. Summary of Product Characteristics. Schering-Plough Europe, Brussels, Belgium. (2005).
   Google Scholar
• Neoclarityn® (desloratadine) 5 mg film-coated tablets. Summary of Product Characteristics. Schering-Plough Europe, Brussels, Belgium (2005).
   Google Scholar
• Heithoff K, Meltzer EO, Mellars L, Salmun LM. Desloratadine improves quality of life in patients with seasonal allergic rhinitis. J. Allergy Clin. Immunol.104, Abstract 1121 (2000).
   Google Scholar
• Tonnel AB, Holmberg K, Sauvage N, Enander I. Desloratadine improves the health-related quality of life in persistent allergic rhinitis. Proceedings of the XXIII EAACI Congress. Amsterdam, The Netherlands. Abstract 260 and poster (2004).
   Google Scholar